August 23, 2010 **UPDATED: October 6, 2010**

Dear Valued Client:

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled the enclosed packet of important changes regarding a number of tests we perform. Listed below are the types of changes included in this packet.

Type of Change	Explanation
New Tests	**Tests recently added to the NMS Labs test menu. New Tests are effective immediately.**
Test Changes	**Tests that have had changes to their method/CPT code, units of measurement, scope of analysis or specimen requirements.** **Updated: 0542U Special Handling**
Discontinued Tests	**Tests being discontinued with alternate testing suggestions.**

Please be advised all changes listed in this packet will go into effect on **December 6, 2010**. Please use this packet of information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this packet, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

Sincerely,

NMS Labs

Database Changes - Summary

Test Code	Test Name	New Test	Method/ CPT code	Units	Scope	Specimen Reqs	Stability	Discontinued	Reference Comment	Misc.
0275SP	Dalfampridine, Serum/Plasma	•								
0275U	Dalfampridine, Urine	•								
0276SP	4-Aminopyridine Exposure, Serum/Plasma	•								
0276U	4-Aminopyridine Exposure, Urine	•								
0490B	Atropine, Blood					•				
0490SP	Atropine, Serum/Plasma					•				
0490U	Atropine, Urine					•				
0520B	Belladonna Alkaloids Panel, Blood					•				
0520SP	Belladonna Alkaloids Panel, Serum/Plasma					•				
0520U	Belladonna Alkaloids Panel, Urine					•				
0542U	Benzene Incident, Urine (OSHA)					•				•
0690B	Bisphenol A - Free (Unconjugated), Blood	•								
0690SP	Bisphenol A - Free (Unconjugated), Serum/Plasma	•								
1033U	Cathartic Laxatives Profile (Qualitative), Urine							•		
1138B	meta-Chlorophenylpiperazine (mCPP) (Forensic), Blood	•								
1138SP	meta-Chlorophenylpiperazine (mCPP) (Forensic), Serum/Plasma	•								
1138U	meta-Chlorophenylpiperazine (mCPP) (Forensic), Urine	•								
1300SP	Cocaine and Metabolites, Serum/Plasma						•			
1925SP	Entacapone and Tolcapone, Serum/Plasma	•								
1926SP	Entacapone, Serum/Plasma	•								
2414B	Inhalants Panel, Halocarbons, Blood				•					
2414SP	Inhalants Panel, Halocarbons, Serum/Plasma				•					
2414TI	Inhalants Panel, Halocarbons, Tissue				•					
2482B	Ketorolac, Blood								•	
2482SP	Ketorolac, Serum/Plasma								•	
2499U	Laxatives Panel (Qualitative), Urine	•								
3223B	Nonsteroidal Anti-Inflammatory Drug Panel, Blood				•				•	
3223SP	Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma				•				•	
3223U	Nonsteroidal Anti-Inflammatory Drug Panel, Urine				•					
3777B	Piperazine Designer Drugs Panel (Forensic), Blood	•								
3777SP	Piperazine Designer Drugs Panel (Forensic), Serum/Plasma	•								
3777U	Piperazine Designer Drugs Panel (Forensic), Urine	•								
3932B	Procainamide and Metabolite, Blood				•					•
3932SP	Procainamide and Metabolite, Serum/Plasma				•					•
3932U	Procainamide and Metabolite, Urine				•					•
4160B	Scopolamine, Blood					•				
4160SP	Scopolamine, Serum/Plasma					•				
4160U	Scopolamine, Urine					•				
4360B	3-Trifluoromethylphenylpiperazine (TFMPP) (Forensic), Blood	•								

Database Changes - Summary

Test Code	Test Name	New Test	Method/ CPT code	Units	Scope	Specimen Reqs	Stability	Discontinued	Reference Comment	Misc.
4360SP	3-Trifluoromethylphenylpiperazine (TFMPP) (Forensic), Serum/Plasma	•								
4360U	3-Trifluoromethylphenylpiperazine (TFMPP) (Forensic), Urine	•								
4503SP	Tolcapone, Serum/Plasma	•								
5454B	Atropine Confirmation, Blood					•				
5454SP	Atropine Confirmation, Serum/Plasma					•				
5454U	Atropine Confirmation, Urine					•				
5583B	Scopolamine Confirmation, Blood					•				
5583SP	Scopolamine Confirmation, Serum/Plasma					•				
5583U	Scopolamine Confirmation, Urine					•				
7625U	Cortisol, Urine	•								
7625UH	Cortisol, 24 Hour Urine	•								
7655U	Cortisol and Cortisone, Urine	•								
7655UH	Cortisol and Cortisone, 24 Hour Urine	•								
7656U	Cortisone, Urine	•								
7656UH	Cortisone, 24 Hour Urine	•								
9109B	Atropine Screen, Blood					•				
9109SP	Atropine Screen, Serum/Plasma					•				
9109U	Atropine Screen, Urine					•				
9261B	Scopolamine Screen, Blood					•				
9261SP	Scopolamine Screen, Serum/Plasma					•				
9261U	Scopolamine Screen, Urine					•				

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
4360B	**3-Trifluoromethylphenylpiperazine (TFMPP) (Forensic), Blood**			
	Scope of Analysis: TFMPP	10	ng/mL	GC/MS (82205)
	Reference Comment: TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsule forms and is commonly only present in products that contain N-benzylpiperazine (N-BZP). TFMPP is often mixed with N-BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). There is little information concerning blood or plasma concentrations of TFMPP. In one study, serum concentrations of TFMPP in 3 drug abusers were reported to be between 260 and 270 ng/mL.			
	Specimen Requirements: Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			
4360SP	**3-Trifluoromethylphenylpiperazine (TFMPP) (Forensic), Serum/Plasma**			
	Scope of Analysis: TFMPP	10	ng/mL	GC/MS (82205)
	Reference Comment: TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsule forms and is commonly only present in products that contain N-benzylpiperazine (N-BZP). TFMPP is often mixed with N-BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). There is little information concerning blood or plasma concentrations of TFMPP. In one study, serum concentrations of TFMPP in 3 drug abusers were reported to be between 260 and 270 ng/mL.			
	Specimen Requirements: Specimen Requirements: 2 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
4360U	**3-Trifluoromethylphenylpiperazine (TFMPP) (Forensic), Urine**			
Scope of Analysis:	TFMPP	10	ng/mL	GC/MS (82205)
Reference Comment:	TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsules and is commonly only present in products that contain N-benzylpiperazine (N-BZP). TFMPP is often mixed with N-BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). The compound is metabolized primarily to hydroxylated derivatives that then may form glucuronide and/or sulfate conjugates. Urine concentrations of the parent compound typically are observed to be between approximately 800 and 1800 ng/mL; however there are two cases in which urine concentrations exceeded 17000 ng/mL.			
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			
0276SP	**4-Aminopyridine Exposure, Serum/Plasma**			
Scope of Analysis:	4-Aminopyridine	2	ng/mL	LC-MS/MS (83789)
Reference Comment:	A plasma concentration of approximately 100 ng/mL is considered a likely threshold for increased risk of seizures.			
Specimen Requirements:	Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
0276U	**4-Aminopyridine Exposure, Urine**			
	Scope of Analysis: 4-Aminopyridine	2	ng/mL	LC-MS/MS (83789)
	Reference Comment: No reference data available.			
	Specimen Requirements: Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			
0690B	**Bisphenol A - Free (Unconjugated), Blood**			
	Scope of Analysis: Bisphenol A - Free	0.25	ng/mL	GC/MS (82542)
	Reference Comment: Studies in humans have measured serum levels of unconjugated (free) bisphenol A ranging between 0.2 and 20 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.			
	Specimen Requirements: Specimen Requirements: 3 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			
0690SP	**Bisphenol A - Free (Unconjugated), Serum/Plasma**			
	Scope of Analysis: Bisphenol A - Free	0.25	ng/mL	GC/MS (82542)
	Reference Comment: Studies in humans have measured serum levels of unconjugated (free) bisphenol A ranging between 0.2 and 20 ng/mL.			
	Specimen Requirements: Specimen Requirements: 3 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a polypropylene plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
7625U	**Cortisol, Urine**			
	Scope of Analysis: Cortisol (Creatinine corrected)	2.5	mcg/g Creat	LC-MS/MS (83789)
	Reference Comment: Reference Intervals for Females: Up to 2 years: 3.0 - 120 mcg/g Creatinine Age 3 - 8 years: 2.2 - 89 mcg/g Creatinine Age 9 - 12 years: 1.4 - 56 mcg/g Creatinine Age 13 - 17 years: 1.0 - 42 mcg/g Creatinine Age 18 years and above: 0.7 - 85 mcg/g Creatinine Reference Intervals for Males: Age 0 - 2 years: 3.0 - 120 mcg/g Creatinine Age 3 - 8 years: 2.2 - 89 mcg/g Creatinine Age 9 - 12 years: 1.4 - 56 mcg/g Creatinine Age 13 - 17 years: 1.0 - 42 mcg/g Creatinine Age 18 years and above: 1.0 - 119 mcg/g Creatinine			
	Specimen Requirements: Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.			
	Stability: Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 6 month(s)			
7625UH	**Cortisol, 24 Hour Urine**			
	Scope of Analysis: Cortisol	2.5	mcg/24 hr	LC-MS/MS (83789)
	Reference Comment: Reference Intervals for patients: Age 3 - 8 years: 3.0 - 8.0 mg/24 hr Age 9 - 12 years: 2.6 - 37 mg/24 hr Age 13 - 17 years: 4.0 - 56 mg/24 hr Age 18 years and above: 3.5 - 45 mg/24 hr			
	Specimen Requirements: Specimen Requirements: 2 mL 24 Hour Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.			
	Stability: Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 6 month(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
7655U	**Cortisol and Cortisone, Urine**			
Scope of Analysis:	Cortisol (Creatinine corrected)	2.5	mcg/g Creat	LC-MS/MS (83789)
Reference Comment:	Reference Intervals for Females: Up to 2 years: 3.0 - 120 mcg/g Creatinine Age 3 - 8 years: 2.2 - 89 mcg/g Creatinine Age 9 - 12 years: 1.4 - 56 mcg/g Creatinine Age 13 - 17 years: 1.0 - 42 mcg/g Creatinine Age 18 years and above: 0.7 - 85 mcg/g Creatinine Reference Intervals for Males: Age 0 - 2 years: 3.0 - 120 mcg/g Creatinine Age 3 - 8 years: 2.2 - 89 mcg/g Creatinine Age 9 - 12 years: 1.4 - 56 mcg/g Creatinine Age 13 - 17 years: 1.0 - 42 mcg/g Creatinine Age 18 years and above: 1.0 - 119 mcg/g Creatinine			
	Cortisone (Creatinine corrected)	2.5	mcg/g Creat	
Reference Comment:	Reference Intervals for patients: Up to 2 years: 35 - 477 mcg/g Creatinine Age 3 - 8 years: 11 - 211 mcg/g Creatinine Age 9 - 12 years: 5.8 - 109 mcg/g Creatinine Age 13 - 17 years: 5.4 - 102 mcg/g Creatinine Age 18 - 29 years: 5.7 - 153 mcg/g Creatinine Age 30 - 39 years: 6.6 - 176 mcg/g Creatinine Age 40 - 49 years: 7.6 - 203 mcg/g Creatinine Age 50 - 59 years: 8.8 - 234 mcg/g Creatinine Age 60 - 69 years: 10 - 270 mcg/g Creatinine Age 70 years and above: 12 - 311 mcg/g Creatinine			
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.			
Stability:	Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 6 month(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
7655UH	**Cortisol and Cortisone, 24 Hour Urine**			
Scope of Analysis:	Cortisol	2.5	mcg/24 hr	LC-MS/MS (83789)
Reference Comment:	Reference Intervals for patients: Age 3 - 8 years: 3.0 - 8.0 mg/24 hr Age 9 - 12 years: 2.6 - 37 mg/24 hr Age 13 - 17 years: 4.0 - 56 mg/24 hr Age 18 years and above: 3.5 - 45 mg/24 hr			
	Cortisone	2.5	mcg/24 hr	
Reference Comment:	Reference Intervals for patients: Age 3 - 8 years: 5.5 - 41 mg/24 hr Age 9 - 12 years: 9.9 - 73 mg/24 hr Age 13 - 17 years: 15 - 108 mg/24 hr Age 18 years and above: 17 - 129 mg/24 hr			
Specimen Requirements:	Specimen Requirements: 2 mL 24 Hour Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.			
Stability:	Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 6 month(s)			
7656U	**Cortisone, Urine**			
Scope of Analysis:	Cortisone (Creatinine corrected)	2.5	mcg/g Creat	LC-MS/MS (83789)
Reference Comment:	Reference Intervals for patients: Up to 2 years: 35 - 477 mcg/g Creatinine Age 3 - 8 years: 11 - 211 mcg/g Creatinine Age 9 - 12 years: 5.8 - 109 mcg/g Creatinine Age 13 - 17 years: 5.4 - 102 mcg/g Creatinine Age 18 - 29 years: 5.7 - 153 mcg/g Creatinine Age 30 - 39 years: 6.6 - 176 mcg/g Creatinine Age 40 - 49 years: 7.6 - 203 mcg/g Creatinine Age 50 - 59 years: 8.8 - 234 mcg/g Creatinine Age 60 - 69 years: 10 - 270 mcg/g Creatinine Age 70 years and above: 12 - 311 mcg/g Creatinine			
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.			
Stability:	Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 6 month(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
7656UH	**Cortisone, 24 Hour Urine**			
	Scope of Analysis: Cortisone	2.5	mcg/24 hr	LC-MS/MS (83789)
	Reference Comment: Reference Intervals for patients: Age 3 - 8 years: 5.5 - 41 mg/24 hr Age 9 - 12 years: 9.9 - 73 mg/24 hr Age 13 - 17 years: 15 - 108 mg/24 hr Age 18 years and above: 17 - 129 mg/24 hr			
	Specimen Requirements: Specimen Requirements: 2 mL 24 Hour Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.			
	Stability: Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 6 month(s)			
0275SP	**Dalfampridine, Serum/Plasma**			
	Scope of Analysis: Dalfampridine	2	ng/mL	LC-MS/MS (83789)
	Reference Comment: Average peak plasma concentrations of dalfampridine (4-Aminopyridine) following a single oral dosage of 10 mg and 20 mg were 25 ng/mL and 49 ng/mL, respectively, 3 to 4 hours post administration.			
	Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
0275U	**Dalfampridine, Urine**			
	Scope of Analysis: Dalfampridine	2	ng/mL	LC-MS/MS (83789)
	Reference Comment: Dalfampridine (4-Aminopyridine) elimination is primarily through the kidneys and is nearly complete after 24 hours. Approximately 90% of the drug excreted in the urine is unchanged.			
	Specimen Requirements: Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			
1926SP	**Entacapone, Serum/Plasma**			
	Scope of Analysis: Entacapone	0.1	mcg/mL	HPLC (82491)
	Reference Comment: A single oral dose (in 12 healthy subjects) resulted in the following approximate mean peak plasma concentrations (+/- SD) within 1 hour: 5 mg: 0.062 +/- 0.025 mcg/mL 25 mg: 0.32 +/- 0.11 mcg/mL 50 mg: 0.56 +/- 0.19 mcg/mL 100 mg: 1.11 +/- 0.22 mcg/mL 200 mg: 1.8 +/- 0.76 mcg/mL 400 mg: 4.3 +/- 2.1 mcg/mL 800 mg: 7.3 +/- 2.7 mcg/mL			
	Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum into a plastic screw capped vial using approved guidelines. Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: Not Stable Refrigerated: 7 day(s) Frozen (-20 °C): 1 month(s) Frozen (-70 °C): 1 month(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
1925SP	**Entacapone and Tolcapone, Serum/Plasma**			
	Scope of Analysis: Entacapone	0.1	mcg/mL	HPLC (82491)
	Reference Comment: A single oral dose (in 12 healthy subjects) resulted in the following approximate mean peak plasma concentrations (+/- SD) within 1 hour: 5 mg: 0.062 +/- 0.025 mcg/mL 25 mg: 0.32 +/- 0.11 mcg/mL 50 mg: 0.56 +/- 0.19 mcg/mL 100 mg: 1.11 +/- 0.22 mcg/mL 200 mg: 1.8 +/- 0.76 mcg/mL 400 mg: 4.3 +/- 2.1 mcg/mL 800 mg: 7.3 +/- 2.7 mcg/mL			
	Tolcapone	0.3	mcg/mL	
	Reference Comment: Patients taking tolcapone three times daily had the following average peak plasma concentrations: 100 mg: 3 mcg/mL 200 mg: 6 mcg/mL			
	Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum into a plastic screw capped vial using approved guidelines. Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: Not Stable Refrigerated: 7 day(s) Frozen (-20 °C): 1 month(s) Frozen (-70 °C): 1 month(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
2499U	**Laxatives Panel (Qualitative), Urine**			
Scope of Analysis:	Desacetyl Bisacodyl	5	ng/mL	LC-MS/MS (83788)
Reference Comment:	As a metabolite of bisacodyl, desacetyl bisacodyl was detected in urine over four days following administration of a 5 mg oral dose. The maximum excretion occurred on day 2 of the study.			
	Rhein	5	ng/mL	
Reference Comment:	Rhein is an anthranoid derivative of natural laxative products. Rhein was detected in urine 32 hours following administration of senna.			
	Emodin	5	ng/mL	
Reference Comment:	Emodin is an anthranoid derivative of natural laxative products. Emodin was detected in urine 12 hours following administration of rhamnus extract.			
	Aloe-Emodin	5	ng/mL	
Reference Comment:	Aloe-Emodin is an anthranoid derivative of natural laxative products.			
Specimen Requirements:	Specimen Requirements: 3 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
1138B	**meta-Chlorophenylpiperazine (mCPP) (Forensic), Blood**			
	Scope of Analysis: mCPP	10	ng/mL	GC/MS (82205)
	Reference Comment: mCPP (meta-Chlorophenylpiperazine) is often encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate. A woman reported to have taken 3 tablets containing 30.3 mg mCPP/tablet (total dose = 90.9 mg) had a plasma mCPP concentration of 320 ng/mL. Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia. mCPP is also an active metabolite of the antidepressants Trazodone and Nefazodone.			
	Specimen Requirements: Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 7 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 7 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
1138SP	**meta-Chlorophenylpiperazine (mCPP) (Forensic), Serum/Plasma**			
	Scope of Analysis: mCPP	10	ng/mL	GC/MS (82205)
	Reference Comment: mCPP (meta-Chlorophenylpiperazine) is often encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate. A woman reported to have taken 3 tablets containing 30.3 mg mCPP/tablet (total dose = 90.9 mg) had a plasma mCPP concentration of 320 ng/mL. Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia. mCPP is also an active metabolite of the antidepressants Trazodone and Nefazodone.			
	Specimen Requirements: Specimen Requirements: 2 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
1138U	**meta-Chlorophenylpiperazine (mCPP) (Forensic), Urine**			
	Scope of Analysis: mCPP	10	ng/mL	GC/MS (82205)
	Reference Comment: mCPP (meta-Chlorophenylpiperazine) is often encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate. Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia. mCPP is also an active metabolite of the antidepressants Trazodone and Nefazodone.			
	Specimen Requirements: Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
3777B	**Piperazine Designer Drugs Panel (Forensic), Blood**			
	Scope of Analysis: TFMPP	10	ng/mL	GC/MS (82205)
	Reference Comment: TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsule forms and is commonly only present in products that contain N-benzylpiperazine (N-BZP). TFMPP is often mixed with N-BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). There is little information concerning blood or plasma concentrations of TFMPP. In one study, serum concentrations of TFMPP in 3 drug abusers were reported to be between 260 and 270 ng/mL.			
	N-BZP	10	ng/mL	
	Reference Comment: Mean peak plasma concentration following a 200 mg oral dose was reported to be 262 ng/mL (range 222 - 344 ng/mL), 75 min post dose. The whole blood to plasma ratio has not been reported for this drug.			
	mCPP	10	ng/mL	
	Reference Comment: mCPP (meta-Chlorophenylpiperazine) is often encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate. A woman reported to have taken 3 tablets containing 30.3 mg mCPP/tablet (total dose = 90.9 mg) had a plasma mCPP concentration of 320 ng/mL. Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia. mCPP is also an active metabolite of the antidepressants Trazodone and Nefazodone.			
	Specimen Requirements: Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 7 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 7 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
3777SP	**Piperazine Designer Drugs Panel (Forensic), Serum/Plasma**			
Scope of Analysis:	TFMPP	10	ng/mL	GC/MS(82205)
Reference Comment:	TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsule forms and is commonly only present in products that contain N-benzylpiperazine (N-BZP). TFMPP is often mixed with N-BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). There is little information concerning blood or plasma concentrations of TFMPP. In one study, serum concentrations of TFMPP in 3 drug abusers were reported to be between 260 and 270 ng/mL.			
	N-BZP	10	ng/mL	
Reference Comment:	Mean peak plasma concentration following a 200 mg oral dose was reported to be 262 ng/mL (range 222 - 344 ng/mL), 75 min post dose.			
	mCPP	10	ng/mL	
Reference Comment:	mCPP (meta-Chlorophenylpiperazine) is often encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate. A woman reported to have taken 3 tablets containing 30.3 mg mCPP/tablet (total dose = 90.9 mg) had a plasma mCPP concentration of 320 ng/mL. Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia. mCPP is also an active metabolite of the antidepressants Trazodone and Nefazodone.			
Specimen Requirements:	Specimen Requirements: 2 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
3777U	**Piperazine Designer Drugs Panel (Forensic), Urine**			
	Scope of Analysis: TFMPP	10	ng/mL	GC/MS (82205)
	Reference Comment: TFMPP is a synthetic piperazine derivative categorized as a 'designer drug'. TFMPP is available in tablet and capsules and is commonly only present in products that contain N-benzylpiperazine (N-BZP). TFMPP is often mixed with N-BZP in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). The compound is metabolized primarily to hydroxylated derivatives that then may form glucuronide and/or sulfate conjugates. Urine concentrations of the parent compound typically are observed to be between approximately 800 and 1800 ng/mL; however there are two cases in which urine concentrations exceeded 17000 ng/mL.			
	N-BZP	10	ng/mL	
	Reference Comment: N-BZP (N-benzylpiperazine, BZP) is a synthetic sympathomimetic compound often categorized as a 'designer drug'. Since the 1990s the compound has gained popularity as a stimulant drug of abuse, having a potency of approximately one-tenth that of dextroamphetamine. N-BZP is often mixed with a similar compound, trifluoromethylphenylpiperazine (TFMPP) in order to mimic the psychoactive effects of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA).			
	mCPP	10	ng/mL	
	Reference Comment: mCPP (meta-Chlorophenylpiperazine) is often encountered in illicit tablets sold as Ecstasy. Reported concentrations of mCPP in these tablets range from 2 - 357 mg/tablet. Tablets may contain only mCPP or may be mixed with other drugs such as MDMA, TFMPP or caffeine. mCPP has similar subjective stimulant and hallucinogenic effects as MDMA, but unlike MDMA has not been found to increase blood pressure or heart rate. Reported adverse effects include nausea, vomiting, dizziness, sweating, induction of migraine-like headache, anxiety, depressive symptoms and paranoia. mCPP is also an active metabolite of the antidepressants Trazodone and Nefazodone.			
	Specimen Requirements: Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)			

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
4503SP	**Tolcapone, Serum/Plasma**			
Scope of Analysis:	Tolcapone	0.3	mcg/mL	HPLC (82491)
Reference Comment:	Patients taking tolcapone three times daily had the following average peak plasma concentrations: 100 mg: 3 mcg/mL 200 mg: 6 mcg/mL			
Specimen Requirements:	Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 1 month(s) Frozen (-70 °C): 1 month(s)			

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
0490B	**Atropine, Blood**		
Specimen Requirements:	Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
0490SP	**Atropine, Serum/Plasma**		
Specimen Requirements:	Specimen Requirements: 3 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
0490U	**Atropine, Urine**		
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
5454B	**Atropine Confirmation, Blood**		
Specimen Requirements:	Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
5454SP	**Atropine Confirmation, Serum/Plasma**		
Specimen Requirements:	Specimen Requirements: 3 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
5454U	**Atropine Confirmation, Urine**		
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
9109B	**Atropine Screen, Blood**		
Specimen Requirements:	Specimen Requirements: 4 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
9109SP	**Atropine Screen, Serum/Plasma**		
Specimen Requirements:	Specimen Requirements: 6 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
9109U	**Atropine Screen, Urine**		
Specimen Requirements:	Specimen Requirements: 3 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
0520B	**Belladonna Alkaloids Panel, Blood**		
Specimen Requirements:	Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Requested Volume was changed. Specimen Container was changed.		
0520SP	**Belladonna Alkaloids Panel, Serum/Plasma**		
Specimen Requirements:	pecimen Requirements: 3 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Requested Volume was changed. Specimen Container was changed.		
0520U	**Belladonna Alkaloids Panel, Urine**		
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Requested Volume was changed. Specimen Container was changed.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
0542U	**Benzene Incident, Urine (OSHA)**		
Specimen Requirements:	Specimen Requirements: 4 mL Urine Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Collect sample at end of shift. Samples must include collection date/time and be received at NMS Labs within 48 hrs of collection. If not, test 0543U Benzene OSHA Exposure will be assigned. Urine samples preserved with Benzoic Acid are unsuitable for analysis. Preservative-free Urine samples are recommended. Rejection Criteria: Received Room Temperature.		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Test Name was changed. Special Handling was changed.		
1300SP	**Cocaine and Metabolites, Serum/Plasma**		
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): 14 day(s)		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Stability was changed.		
2414B	**Inhalants Panel, Halocarbons, Blood**		
	Carbon Tetrachloride Chloroform Dichloromethane **Trichlorofluoromethane** **Dichlorodifluoromethane** **Trichlorotrifluoroethane** Methyl Chloroform Perchloroethylene Trichloroethylene		GC (84600)
Summary of Updates:	For Quality Improvement purposes the following updates were made. Freon 11, Freon 12 and Freon 113 were removed. Trichlorofluoromethane, Dichlorodifluoromethane and Trichlorotrifluoroethane were added.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
2414SP	**Inhalants Panel, Halocarbons, Serum/Plasma**		
	Carbon Tetrachloride Chloroform Dichloromethane **Trichlorofluoromethane** **Dichlorodifluoromethane** **Trichlorotrifluoroethane** Methyl Chloroform Perchloroethylene Trichloroethylene		GC (84600)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Freon 11, Freon 12 and Freon 113 were removed. Trichlorofluoromethane, Dichlorodifluoromethane and Trichlorotrifluoroethane were added.		
2414TI	**Inhalants Panel, Halocarbons, Tissue**		
	Carbon Tetrachloride Chloroform Dichloromethane **Trichlorofluoromethane** **Dichlorodifluoromethane** **Trichlorotrifluoroethane** Methyl Chloroform Perchloroethylene Trichloroethylene		GC (80103, 84600)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Freon 11, Freon 12 and Freon 113 were removed. Trichlorofluoromethane, Dichlorodifluoromethane and Trichlorotrifluoroethane were added.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
3223B	**Nonsteroidal Anti-Inflammatory Drug Panel, Blood** Piroxicam Ketorolac **6-MNA** Tolmetin Ketoprofen Naproxen Oxaprozin Fenoprofen Etodolac Flurbiprofen Indomethacin Ibuprofen Diclofenac		HPLC (82492)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Nabumetone as 6-MNA was removed. 6-MNA was added.		
3223SP	**Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma** Piroxicam Ketorolac **6-MNA** Tolmetin Ketoprofen Naproxen Oxaprozin Fenoprofen Etodolac Flurbiprofen Indomethacin Ibuprofen Diclofenac		HPLC (82492)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Nabumetone as 6-MNA was removed. 6-MNA was added.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
3223U	**Nonsteroidal Anti-Inflammatory Drug Panel, Urine** Piroxicam Ketorolac **6-MNA** Tolmetin Ketoprofen Naproxen Oxaprozin Fenoprofen Etodolac Flurbiprofen Indomethacin Ibuprofen Diclofenac		HPLC (82492)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Nabumetone as 6-MNA was removed. 6-MNA was added.		
3932B	**Procainamide and Metabolite, Blood** Procainamide **N-Acetylprocainamide**		HPLC (80192)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Test Name was changed. NAPA was removed. N-Acetylprocainamide was added.		
3932SP	**Procainamide and Metabolite, Serum/Plasma** Procainamide **N-Acetylprocainamide**		HPLC (80192)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Test Name was changed. NAPA was removed. N-Acetylprocainamide was added.		
3932U	**Procainamide and Metabolite, Urine** Procainamide **N-Acetylprocainamide**		HPLC (80192)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Test Name was changed. NAPA was removed. N-Acetylprocainamide was added.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
4160B	**Scopolamine, Blood**		
Specimen Requirements:	Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
4160SP	**Scopolamine, Serum/Plasma**		
Specimen Requirements:	Specimen Requirements: 3 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
4160U	**Scopolamine, Urine**		
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
5583B	**Scopolamine Confirmation, Blood**		
Specimen Requirements:	Specimen Requirements: 2 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
5583SP	**Scopolamine Confirmation, Serum/Plasma**		
Specimen Requirements:	Specimen Requirements: 3 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
5583U	**Scopolamine Confirmation, Urine**		
Specimen Requirements:	Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
9261B	**Scopolamine Screen, Blood**		
Specimen Requirements:	Specimen Requirements: 3 mL Blood Transport Temperature: Refrigerated Specimen Container: Lavender top tube (EDTA) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		
9261SP	**Scopolamine Screen, Serum/Plasma**		
Specimen Requirements:	Specimen Requirements: 5 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

TEST UPDATES
Method/CPT Code*, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
9261U	**Scopolamine Screen, Urine**		
Specimen Requirements:	Specimen Requirements: 3 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
Summary of Updates:	For Quality Improvement purposes the following updates were made. Specimen Container was changed.		

DISCONTINUED TESTS

Test Code	Test Name	Alternative Test
1033U	Cathartic Laxatives Profile (Qualitative), Urine	2499U Laxatives Panel (Qualitative), Urine

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

REFERENCE COMMENT CHANGES

Test Code	Test Name / Compound	New Reference Comment
2482B	**Ketorolac, Blood** • Ketorolac	The mean peak plasma concentration following a single IV dose: 15 mg dose: 2.5 mcg/mL (within 3 min; adults) 30 mg dose: 4.75 mcg/mL (within 3 min; adults) 0.6 mg/kg dose: 4.3 mcg/mL (in 10 min; children 3 - 18 years) Mean plasma concentration following IV doses 4 times daily in adults: 15 mg doses: 3.1 mcg/mL (peak) and 1.1 mcg/mL (steady-state) 30 mg doses: 6.9 mcg/mL (peak) and 2.2 mcg/mL (steady-state) Mean peak plasma concentration following a single IM dose (30-60 min) in adults: 10 mg dose: 0.7 - 1.4 mcg/mL 30 mg dose: 2.2 - 3.0 mcg/mL 60 mg dose: 4.0 - 4.6 mcg/mL 90 mg dose: 6.9 mcg/mL Mean steady-state plasma concentration following IM doses 4 times daily in adults: 15 mg doses: 0.7 mcg/mL (range, 0.2 - 1.7 mcg/mL) 30 mg doses: 1.4 mcg/mL (range, 0.3 - 3.5 mcg/mL) Mean peak plasma concentration (20 to 60 minutes) following a single oral dose in adults: 10 mg dose: 0.7 - 1.1 mcg/mL 30 mg dose: 2.7 mcg/mL The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

REFERENCE COMMENT CHANGES

Test Code	Test Name / Compound	New Reference Comment
2482SP	**Ketorolac, Serum/Plasma** • **Ketorolac**	The mean peak plasma concentration following a single IV dose: 15 mg dose: 2.5 mcg/mL (within 3 min; adults) 30 mg dose: 4.75 mcg/mL (within 3 min; adults) 0.6 mg/kg dose: 4.3 mcg/mL (in 10 min; children 3 - 18 years) Mean plasma concentration following IV doses 4 times daily in adults: 15 mg doses: 3.1 mcg/mL (peak) and 1.1 mcg/mL (steady-state) 30 mg doses: 6.9 mcg/mL (peak) and 2.2 mcg/mL (steady-state) Mean peak plasma concentration following a single IM dose (30-60 min) in adults: 10 mg dose: 0.7 - 1.4 mcg/mL 30 mg dose: 2.2 - 3.0 mcg/mL 60 mg dose: 4.0 - 4.6 mcg/mL 90 mg dose: 6.9 mcg/mL Mean steady-state plasma concentration following IM doses 4 times daily in adults: 15 mg doses: 0.7 mcg/mL (range, 0.2 - 1.7 mcg/mL) 30 mg doses: 1.4 mcg/mL (range, 0.3 - 3.5 mcg/mL) Mean peak plasma concentration (20 to 60 minutes) following a single oral dose in adults: 10 mg dose: 0.7 - 1.1 mcg/mL 30 mg dose: 2.7 mcg/mL

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

REFERENCE COMMENT CHANGES

Test Code	Test Name / Compound	New Reference Comment
3223B	**Nonsteroidal Anti-Inflammatory Drug Panel, Blood** • Ketorolac	The mean peak plasma concentration following a single IV dose: 15 mg dose: 2.5 mcg/mL (within 3 min; adults) 30 mg dose: 4.75 mcg/mL (within 3 min; adults) 0.6 mg/kg dose: 4.3 mcg/mL (in 10 min; children 3 - 18 years) Mean plasma concentration following IV doses 4 times daily in adults: 15 mg doses: 3.1 mcg/mL (peak) and 1.1 mcg/mL (steady-state) 30 mg doses: 6.9 mcg/mL (peak) and 2.2 mcg/mL (steady-state) Mean peak plasma concentration following a single IM dose (30-60 min) in adults: 10 mg dose: 0.7 - 1.4 mcg/mL 30 mg dose: 2.2 - 3.0 mcg/mL 60 mg dose: 4.0 - 4.6 mcg/mL 90 mg dose: 6.9 mcg/mL Mean steady-state plasma concentration following IM doses 4 times daily in adults: 15 mg doses: 0.7 mcg/mL (range, 0.2 - 1.7 mcg/mL) 30 mg doses: 1.4 mcg/mL (range, 0.3 - 3.5 mcg/mL) Mean peak plasma concentration (20 to 60 minutes) following a single oral dose in adults: 10 mg dose: 0.7 - 1.1 mcg/mL 30 mg dose: 2.7 mcg/mL The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com

REFERENCE COMMENT CHANGES

Test Code	Test Name / Compound	New Reference Comment
3223SP	**Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma** • **Ketorolac**	The mean peak plasma concentration following a single IV dose: 15 mg dose: 2.5 mcg/mL (within 3 min; adults) 30 mg dose: 4.75 mcg/mL (within 3 min; adults) 0.6 mg/kg dose: 4.3 mcg/mL (in 10 min; children 3 - 18 years) Mean plasma concentration following IV doses 4 times daily in adults: 15 mg doses: 3.1 mcg/mL (peak) and 1.1 mcg/mL (steady-state) 30 mg doses: 6.9 mcg/mL (peak) and 2.2 mcg/mL (steady-state) Mean peak plasma concentration following a single IM dose (30-60 min) in adults: 10 mg dose: 0.7 - 1.4 mcg/mL 30 mg dose: 2.2 - 3.0 mcg/mL 60 mg dose: 4.0 - 4.6 mcg/mL 90 mg dose: 6.9 mcg/mL Mean steady-state plasma concentration following IM doses 4 times daily in adults: 15 mg doses: 0.7 mcg/mL (range, 0.2 - 1.7 mcg/mL) 30 mg doses: 1.4 mcg/mL (range, 0.3 - 3.5 mcg/mL) Mean peak plasma concentration (20 to 60 minutes) following a single oral dose in adults: 10 mg dose: 0.7 - 1.1 mcg/mL 30 mg dose: 2.7 mcg/mL